Wei Ling1, Jie Fan, Yue Ma, Yuan Ma, Hongxia Wang. 1. Department of Oncology, Shanghai Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200127, China.
Abstract
PURPOSE: Metastatic colorectal cancer (MCRC) remains a significant public health concern. The objectives of present study are to investigate the efficacy and safety profile of capecitabine-based chemotherapy in the treatment of MCRC. MATERIALS AND METHODS: We performed a computerized search using combinations of the following keywords: "metastatic colorectal cancer," "Xeloda," "chemotherapy," "capecitabine," or "5-fluorouracil." RESULTS: Treatment with capecitabine chemotherapy was associated with a significantly prolonged progression-free survival (WMD = 1.24; 95% CI, 0.04-2.44; P = 0.04), whereas overall survival was not statistically significant (WMD [random] = 0.29; P = 0.75). Patients in both capecitabine and 5-fluorouracil groups had equal 1-, 2-, and 3-year survival (OR = 0.82, 95% CI: 0.59-1.12, P = 0.21; OR = 0.84, 95% CI: 0.61-1.15, P = 0.27; OR = 1.26, 95% CI: 0.78-2.05, P = 0.34; respectively). The analysis also demonstrates that the response rate of capecitabine-based chemotherapy was comparable to 5-fluorouracil-based chemotherapy (OR = 1.02, 95% CI, 0.90-1.14; P = 0.80). When comparing single-agent capecitabine against 5-fluorouracil/leucovorin, our results showed an overall OR of 1.56 (95% CI, 1.16-2.09) in favor of the capecitabine arm. When toxicity was evaluated, a statistically significant benefit with capecitabine-based therapy was seen, especially for grade 3/4 neutropenia (OR, 0.80; 95% CI, 0.71-0.91; P = 0.00005). CONCLUSIONS: Capecitabine-based chemotherapy demonstrated a significantly superior progression-free survival, equivalent overall survival, and comparable response rate with 5-fluorouracil-based chemotherapy. These observations support the use of capecitabine-based chemotherapy in the treatment of MCRC as a first-line or as a neoadjuvant modality.
PURPOSE:Metastatic colorectal cancer (MCRC) remains a significant public health concern. The objectives of present study are to investigate the efficacy and safety profile of capecitabine-based chemotherapy in the treatment of MCRC. MATERIALS AND METHODS: We performed a computerized search using combinations of the following keywords: "metastatic colorectal cancer," "Xeloda," "chemotherapy," "capecitabine," or "5-fluorouracil." RESULTS: Treatment with capecitabine chemotherapy was associated with a significantly prolonged progression-free survival (WMD = 1.24; 95% CI, 0.04-2.44; P = 0.04), whereas overall survival was not statistically significant (WMD [random] = 0.29; P = 0.75). Patients in both capecitabine and 5-fluorouracil groups had equal 1-, 2-, and 3-year survival (OR = 0.82, 95% CI: 0.59-1.12, P = 0.21; OR = 0.84, 95% CI: 0.61-1.15, P = 0.27; OR = 1.26, 95% CI: 0.78-2.05, P = 0.34; respectively). The analysis also demonstrates that the response rate of capecitabine-based chemotherapy was comparable to 5-fluorouracil-based chemotherapy (OR = 1.02, 95% CI, 0.90-1.14; P = 0.80). When comparing single-agent capecitabine against 5-fluorouracil/leucovorin, our results showed an overall OR of 1.56 (95% CI, 1.16-2.09) in favor of the capecitabine arm. When toxicity was evaluated, a statistically significant benefit with capecitabine-based therapy was seen, especially for grade 3/4 neutropenia (OR, 0.80; 95% CI, 0.71-0.91; P = 0.00005). CONCLUSIONS:Capecitabine-based chemotherapy demonstrated a significantly superior progression-free survival, equivalent overall survival, and comparable response rate with 5-fluorouracil-based chemotherapy. These observations support the use of capecitabine-based chemotherapy in the treatment of MCRC as a first-line or as a neoadjuvant modality.
Authors: E Van Cutsem; C Twelves; J Cassidy; D Allman; E Bajetta; M Boyer; R Bugat; M Findlay; S Frings; M Jahn; J McKendrick; B Osterwalder; G Perez-Manga; R Rosso; P Rougier; W H Schmiegel; J F Seitz; P Thompson; J M Vieitez; C Weitzel; P Harper Journal: J Clin Oncol Date: 2001-11-01 Impact factor: 44.544
Authors: Ahmedin Jemal; Taylor Murray; Elizabeth Ward; Alicia Samuels; Ram C Tiwari; Asma Ghafoor; Eric J Feuer; Michael J Thun Journal: CA Cancer J Clin Date: 2005 Jan-Feb Impact factor: 508.702
Authors: Bruno Reigner; Toru Watanabe; Johannes Schüller; Helen Lucraft; Yasutsuna Sasaki; John Bridgewater; Toshiaki Saeki; James McAleer; Masaru Kuranami; Christopher Poole; Mitsunori Kimura; Jayne Monkhouse; Cahit Yorulmaz; Erhard Weidekamm; Susan Grange Journal: Cancer Chemother Pharmacol Date: 2003-05-29 Impact factor: 3.333
Authors: C-H Köhne; J De Greve; J T Hartmann; I Lang; P Vergauwe; K Becker; D Braumann; E Joosens; L Müller; J Janssens; C Bokemeyer; P Reimer; H Link; E Späth-Schwalbe; H-J Wilke; H Bleiberg; J Van Den Brande; M Debois; U Bethe; E Van Cutsem Journal: Ann Oncol Date: 2007-12-06 Impact factor: 32.976
Authors: K Sumpter; C Harper-Wynne; D Cunningham; S Rao; N Tebbutt; A R Norman; C Ward; T Iveson; M Nicolson; T Hickish; M Hill; J Oates Journal: Br J Cancer Date: 2005-06-06 Impact factor: 7.640